Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Ecstasy Faces Stumbling Blocks To FDA Approval
FDA rejection of Lykos Therapeutics' MDMA application for PTSD treatment led to layoffs and CEO change, opening opportunities for PharmAla Biotech to supply MDMA for clinical trials. PharmAla focuses on non-U.S. markets and plans physician education for MDMA use in PTSD and other mental health conditions.
Biotechnology Market Share Expected to Surge to USD 6.24
The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children aged 1-11 years
CHMP recommends EU approval of Dupixent for eosinophilic esophagitis in children aged 1-11 years, based on phase 3 study showing histological remission. If approved, it would be the first treatment for this age group in the EU.
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic ...
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Dupixent® (dupilumab) Recommended for EU Approval by the
CHMP recommends Dupixent for EoE in children aged 1-11, based on Phase 3 trial showing histological remission. If approved, it would be the first EU treatment for this age group.
Hemophilia B Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.
Adrenoleukodystrophy Clinical Trials 2024: EMA, PDMA, FDA
DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.
HotSpot Therapeutics Appoints Alison O'Neill, M.D., as Chief Medical Officer
HotSpot Therapeutics appoints Dr. Alison O'Neill as Chief Medical Officer, leveraging her extensive biopharmaceutical experience to advance their pipeline of allosteric drug candidates for cancer and autoimmune diseases.
Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
Tandem Diabetes Care receives clearance for t:slim X2 pump with Eli Lilly's Lyumjev ultra-rapid-acting insulin in Europe, expanding its automated insulin delivery system options.
© Copyright 2025. All Rights Reserved by MedPath